Introduction to the FRONTIER 1 Trial <\/p>\n
The FRONTIER 1 trial has recently revealed exciting news for patients suffering from moderate-to-severe plaque psoriasis. The study focused on the efficacy of the oral interleukin-23receptor antagonist peptide, JNJ-77242113. The results demonstrated a clear dose-response relationship, with the compound proving more effective than a placebo within a 16-week timeframe. This article will delve into the details of the FRONTIER 1 trial, its results, and what they mean for the future of psoriasis treatment. <\/p>\n
JNJ-77242113 is the first and only targeted oral peptide that selectively blocks the IL-23 receptor. It has shown positive results in a Phase 2b study for moderate-to-severe plaque psoriasis, achieving the primary and all secondary endpoints. These endpoints included PASI 100 and IGA 0 responses of 40.5 percent and 45.2 percent respectively. The study showed a significant dose response on PASI 75 at Week 16 for adult patients who received JNJ-77242113 compared to patients treated with placebo. This makes it a promising candidate for future oral therapies that may offer an attractive and convenient treatment option for patients. <\/p>\n
The drug JNJ 77242113 showed high response rates of 37 to 79 in moderate-to-severe plaque psoriasis in the FRONTIER 1 phase II trial. Patients treated with a placebo had a 9% response rate at 16 weeks. The most common adverse events were COVID 19 and nasopharyngitis. However, promising progress was shown in the treatment of moderate-to-severe psoriasis. The percentage of patients who had a PASI 90 response with JNJ 77242113 100 mg twice daily at week 16 was 60%. Despite these positive results, two occurrences of infection and a suicide attempt were reported as serious adverse events, indicating the necessity for larger trials to determine the cause of these events and the effectiveness of JNJ 77242113 in real-world settings. <\/p>\n
The Phase II trial results of JNJ-77242113 have instigated the pivotal Phase 3 ICONIC clinical development program. This program aims to confirm the safety and efficacy of this promising new treatment in adult and adolescent patients. In comparison to injectable biologics, JNJ-77242113 showed a similar PASI 90 response rate of 60% at 16 weeks. This suggests that oral therapies could provide a viable alternative to injectables, offering greater flexibility, convenience, and effectiveness. Other oral therapies, like deucravacitinib, are also under development and show promise in revolutionizing psoriasis treatment. <\/p>\n
The future of psoriasis treatment looks promising, particularly with the development of oral therapies such as JNJ-77242113. The results of the FRONTIER 1 trial offer a beacon of hope for patients dealing with moderate-to-severe plaque psoriasis. As we anticipate the results of the ICONIC clinical development program, the potential benefits of introducing an oral route of medication administration for patients with psoriasis is an exciting prospect. As research continues, the goal remains to provide safe, effective, and convenient treatment options for all psoriasis patients. <\/p>\n
<\/p>\n
See the original post: Introduction to the FRONTIER 1 Trial The FRONTIER 1 trial has recently revealed exciting news for patients suffering from moderate-to-severe plaque psoriasis. Continue reading
\nPromising Results from the FRONTIER 1 Trial - An Exploration of JNJ-77242113 in the Treatment of Moderate-to ... - Medriva<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"